Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Summary
This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.
Timeline
- Start
- 2009-06-05
- Primary completion
- 2019-01-11
- Completion
- 2028-10
Outcome
Met primary endpoint
registry NUMBER Stanford V Chemotherapy: 77 (64 to 87) percentage of participants NCT00846742 ↗
registry analysis (superiority test); Stanford V Chemotherapy; p = 0.0003; Exact Binominal Test NCT00846742 ↗
paper of whom 55 (76.4%) achieved a CR at all sites and did not receive RT. PMID 41529162 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Vinblastine | Small molecule | — | Intravenous |
| Subject | Vincristine | Small molecule | — | Intravenous |
| Subject | mechlorethamine | Small molecule | — | Intravenous |